Real-world evidence on first- and second-line palliative chemotherapy in advanced pancreatic cancer

Table 5 Real-world studies of second-line treatment with Folfirinox following failure of gemcitabine/nab-paclitaxel or single-agent gemcitabine[46-51]

Ref.	n	M1	1L regimen	2L regimen	mPFS in mo	mOS in mo	Remarks
Sawada et al[46], 2020	104	100%	GnP	Modified; FFX	3.9	7.0	Bolus 5-FU omitted. 55% grade 3-4 toxicity
Matsumoto et al[47], 2020	23	83%	GnP	FFX 12; mFFX 11	5.3; 4.3	6.9; 12.8	No sign difference in toxicity between FFX/mFFX
Assaf et al[50], 2011	27	100%	Gem	FFX	3.0	8.5	56% grade 3-4 neutropenia
Kobayashi et al[48], 2017	18	100%	Gem	FFX	2.8	9.8	Phase I/II. 83% grade 3-4 toxicity
Kim et al[51], 2018	39	82%	Gem	Attenuated; FFX	3.8	8.5	Oxaliplatin: 65 mg/m2. 41% grade 3-4 neutropenia
Chung et al[49], 2018	48	79%	Gem	Reduced irinotecan and oxaliplatin; FFX	5.8	9.0	Phase IIIrinotecan: 120 mg/m2; Oxaliplatin: 60 mg/m2; 65% grade 3-4 neutropenia

5-FU: Fluorouracil infusion; FFX: Folfirinox; Gem: Gemcitabine; GnP: Gemcitabine/Nab-paclitaxel; M1: Metastatic disease; mFFX: Modified Folfirinox; mOS: Median overall survival; mPFS: Median progression-free survival.